Click to download or view mobile version Author(s): Abstract or description: More Virtual Posters Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension ADD THE FIRST COMMENT If you are a health practitioner, you may Login/Register to comment.Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.